Objective. Apelin/APJ signaling has been determined to regulate cardiac and arterial fibrosis and to be involved in the pathogenesis of pulmonary arterial hypertension. Our objective was to elucidate the role of apelin in skin fibrosis in systemic sclerosis (SSc).
Methods. Expression of apelin/APJ in normal and SSc fibroblasts was compared. Effects of small interfering RNA depletion and the addition of apelin in fibroblasts were analyzed. The effect of apelin injections on bleomycin-induced dermal fibrosis in mice was investigated. We analyzed the effects of the biased agonist of APJ, MM07, on skin fibrosis in vitro and in vivo.
Results. The expression of apelin in SSc fibroblasts was significantly lower than that in normal fibroblasts. Serum apelin levels were negatively correlated with the modified Rodnan skin thickness score in SSc patients. Stimulation with transforming growth factor b1 (TGFb1) inhibited apelin expression in fibroblasts, suggesting that activation of TGFb1 signaling in SSc might be responsible for reduced apelin expression in SSc fibroblasts. Small interfering RNA depletion of apelin from fibroblasts significantly enhanced fibrosis-related gene expression, and treatment with apelin protein significantly inhibited TGFb1 signaling in fibroblasts. Administration of apelin significantly inhibited bleomycin-induced dermal fibrosis in mice. We demonstrated that MM07 had greater potential than apelin to inhibit fibrosis in vivo and in vitro.
Conclusion. Collectively, TGFb1 signaling and apelin signaling may counteract each other in the fibrotic process of SSc. Inhibitory regulation of TGFb1-induced skin fibrosis by apelin/APJ signaling may be involved in the pathogenesis of SSc and could be a therapeutic target for fibrosis in SSc patients.
Systemic sclerosis (SSc) is an autoimmune connective tissue disorder characterized by the development of fibrosis in the skin and internal organs as well as by vascular dysfunction, including Raynaud's phenomenon (RP), digital ulcers, and pulmonary arterial hypertension (PAH) (1) (2) (3) (4) (5) . These complications account for the high morbidity and mortality of SSc patients. Although several treatments for vascular dysfunction are approved, there are no approved targeted therapies for fibrosis. Therefore, there is a great need for novel therapies for fibrosis.
The secreted protein apelin is a selective endogenous ligand of the G protein-coupled receptor APJ, and apelin/APJ signaling mainly regulates cardiovascular functions, fluid homeostasis, angiogenesis, and adipose tissue functions (6) (7) (8) (9) (10) (11) (12) (13) . Apelin expression is widely distributed in various peripheral tissues and is mainly produced by vascular endothelial cells (ECs), adipocytes, and epithelial cells (6) (7) (8) (9) (10) (11) (12) (13) . APJ is expressed ubiquitously, especially in ECs and vascular smooth muscle cells (VSMCs) (6) (7) (8) (9) (10) (11) (12) (13) .
Regarding the regulation of cardiovascular functions, it has been reported that apelin is secreted by ECs and pericytes and binds to APJ, resulting in the dilation of blood vessels and increased blood flow (9, 10) . Apelin/APJ signaling also regulates the parallel alignment of arteries and veins in the skin (11) . Many studies have indicated the important roles of apelin/APJ signaling in the pathogenesis of cardiovascular diseases, including atherosclerosis, coronary heart disease, heart failure, hypertension, myocardial ischemia-reperfusion injury, and PAH (12) (13) (14) (15) (16) (17) (18) . Recently, it has been reported that the expression of apelin in pulmonary arterial ECs in PAH patients was significantly reduced. In addition, the down-regulation of apelin/APJ signaling induced the inhibition of microRNA-424/503 (miR-424/503) and enhanced the expression of fibroblast growth factor 2 (FGF-2) and its receptor FGF receptor 1 (FGFR-1), resulting in EC and VSMC proliferation (12) . It has also been reported that hypoxia-induced PAH was exacerbated in apelin-knockout mice (13) . These findings suggest that decreased apelin expression in ECs is associated with the pathogenesis of PAH.
There is growing evidence that apelin is associated with tissue fibrosis. Interstitial fibrosis of the heart was enhanced in apelin-knockout mice with chronic pressure overload by surgical constriction of the aorta (14, 15) . Apelin/APJ signaling inhibited cardiac fibrosis by inhibiting transforming growth factor b (TGFb) signaling (16, 17) . Also, it has been reported that administration of apelin significantly inhibited TGFb-induced epithelial-mesenchymal transition and attenuated unilateral ureteral obstruction-induced renal tubulointerstitial fibrosis (19, 20) . In contrast, several studies showed that activated apelin/APJ signaling was associated with the initiation and maintenance of liver fibrosis (21, 22) .
With respect to the role of apelin in SSc, a recent study has shown that the prevalence of severe vascular involvement, including intractable skin ulcers, renal crisis, and PAH, was significantly higher in patients with elevated serum apelin levels in late stage SSc (>10 years), suggesting that apelin might be involved in the pathogenesis of vasculopathy in SSc (23) . However, the roles of apelin in the development of skin fibrosis in SSc have not been fully investigated. In this study, we examined the association of serum apelin levels with clinical and laboratory features in SSc patients, the effect of small interfering RNA (siRNA) depletion of apelin and the effect of the addition of apelin on fibrosis in fibroblasts in vitro, and the effect of apelin injections on bleomycininduced dermal fibrosis in mice. Furthermore, we examined the effect of the synthetic biased agonist of APJ, MM07 (24, 25) , on fibrosis in vitro and in vivo.
PATIENTS AND METHODS
Patients and clinical assessments. All SSc patients fulfilled the preliminary classification criteria of the American College of Rheumatology (ACR) (26) and the ACR/European League Against Rheumatism 2013 classification criteria (27) . Sera were obtained from 67 Japanese patients with SSc (61 women, mean AE SD age 60 AE 2.3 years). Of these 67 patients, 41 had limited cutaneous SSc (lcSSc) and 26 had diffuse cutaneous SSc (dcSSc) according to the classification by LeRoy et al (28) . Skin sclerosis was assessed using the modified Rodnan skin thickness score (MRSS) (29) . We obtained human dermal fibroblasts from skin biopsy samples from the affected dorsal forearm areas of 5 dcSSc patients and 7 age-, race-, and sexmatched healthy volunteers. For immunohistochemical staining of apelin, we obtained human skin tissues from skin biopsy samples from the affected dorsal forearm areas of 11 dcSSc patients and 8 age-, race-, and sex-matched healthy volunteers. The study was approved by the institutional review board and the local research ethics committee of Gunma University. All of the patients and volunteers provided informed consent before participating in the study. This study was conducted according to the principles of the Declaration of Helsinki.
Interstitial lung disease (ILD) was defined as the presence of bibasilar interstitial fibrosis or a ground-glass shadow on high-resolution computed tomography scans. PAH was defined as an elevated right ventricular systolic pressure (>35 mm Hg) as assessed by echocardiography and subsequently as an elevated mean pulmonary artery pressure (>25 mm Hg) as assessed by cardiac catheterization.
Cell culture. Human dermal fibroblasts were cultured in Dulbecco's modified Eagle's medium (DMEM) and 10% fetal bovine serum and were used before passage 8.
Reverse transcription-polymerase chain reaction (RT-PCR) analysis. Human dermal fibroblasts were incubated in DMEM with or without [Pyr 1 ]-Apelin-13 (Tocris), MM07 (cyclo [1] [2] [3] [4] [5] [6] CRPRLCHKGPMPF; synthesized by Sigma-Aldrich) (25) , or recombinant human TGFb1 (R&D Systems) for the indicated periods of time. To examine the effect of apelin on production of TGFb1-induced a-smooth muscle actin (a-SMA), collagen a1(I), tissue inhibitor of metalloproteinases 1 (TIMP-1), and sphingosine kinase 1 (SPK-1), the cells were pretreated with apelin or MM07 for 60 minutes and then stimulated with TGFb1 (1 ng/ml) for 24 hours. To inhibit the expression of apelin, siRNA specific for human apelin messenger RNA (mRNA) was designed by and purchased from Thermo Fisher Scientific. Human dermal fibroblasts (5 9 10 5 cells per 60-mm plate) were transfected with 10 nM apelin siRNA or AllStars negative control siRNA (Qiagen) using HiPerFect Transfection Reagent (Qiagen). After 48 hours, apelin, a-SMA, collagen a1(I), TIMP-1, SPK-1, TGFb1, connective tissue growth factor (CTGF), and 18S mRNA levels were assessed by qRT-PCR.
Histochemical and immunofluorescence staining. Dermal fibroblasts from SSc patients or normal individuals were seeded in 8-well culture slides (BD Biosciences). Cells were then either left untreated or treated with TGFb1 (1 ng/ml) and [Pyr 1 ]-Apelin-13 (100 nM) or MM07 (10 nM) for 24 hours and fixed in 4% paraformaldehyde (PFA) in phosphate buffered saline (PBS) at room temperature for 1 hour. Frozen sections (4-lm thick) of human skin were also fixed in 4% PFA. After being blocked with 3% skim milk-PBS supplemented with 5% normal goat serum for 30 minutes at room temperature, cells were stained with rabbit anti-apelin antibody (Santa Cruz Biotechnology), rabbit anti-human APJ antibody (Abcam), anti-a-SMA antibody (Sigma), and anti-fibroblast surface protein antibody (Abcam) followed by Alexa Fluor 488-or Alexa Fluor 568-conjugated secondary antibodies (Invitrogen). Cells were mounted in ProLong Gold antifade reagent (Invitrogen). Quantification of the amount of staining was performed using ImageJ software version 1.46r (National Institutes of Health).
Next, 4-lm-thick sections of mouse skin tissue embedded in paraffin were stained with hematoxylin and eosin or Masson's trichrome. Skin fibrosis was quantified by measuring the thickness of the dermis, which was defined as the distance 1662 YOKOYAMA ET AL from the epidermal-dermal junction to the dermal-subcutaneous junction, at 6 randomly selected microscopic fields. For immunohistochemical staining, tissue sections of human or mouse skin were treated for antigen retrieval with a pressure cooker for 10 minutes at 121°C. After blocking using Peroxidase Blocking (Dako) for 5 minutes and Protein Block (Dako) for 10 minutes, the sections were incubated with rabbit antiapelin antibody, anti-a-SMA antibody, anti-CD3 antibody (Abcam), anti-CD68 antibody (AbD Serotec), and anti-CD31 antibody (Abcam). After washing, the sections were incubated with a horseradish peroxidase-labeled polymer-conjugated secondary antibody (ENVISION+; Dako). Finally, color was developed with 3,3 0 -diaminobenzidine tetrahydrochloride. Western blotting. Western blot analyses were performed according to previously described protocols (30) . To examine the effect of apelin or MM07 on TGFb1-induced a-SMA or collagen a1(I) production, cells were pretreated with [Pyr Bleomycin-induced skin fibrosis model. Dermal fibrosis was induced in 8-week-old C57BL/6 mice with injections of bleomycin. Injections of 300 ll of bleomycin (Nippon Kayaku) at a concentration of 1 mg/ml were given 5 times per week for 2 weeks as previously described (31, 32) . Injections of 300 ll of PBS were used as controls for treatment with bleomycin. To examine the effect of apelin, mice received intraperitoneally [Pyr 1 ]-Apelin-13 (0.1 lmoles/kg/day) dissolved in 100 ll of PBS or PBS alone 5 times per week for 2 weeks. To examine the effect of MM07, mice received intraperitoneally MM07 (0.01 lmoles/kg/day) dissolved in 100 ll of PBS or PBS alone 5 times per week for 2 weeks. In the therapeutic model, apelin or MM07 intraperitoneal injection was initiated 7 days after starting bleomycin treatment. C57BL/6 mice were purchased from Japan SLC. Mice were maintained in the Institute of Experimental Animal Research of Gunma University under specific pathogen-free conditions. All experiments were approved by the Gunma University Animal Care and Experimentation Committee and carried out in accordance with approved guidelines.
Measurement of serum apelin concentration. A specific enzyme-linked immunosorbent assay (ELISA) kit for human apelin-36 (Phoenix Pharmaceuticals) was used for measuring serum apelin levels. This ELISA kit has cross-reactivity with human apelin-12 and apelin-13; therefore, the summation of serum human apelin-12, apelin-13, and apelin-36 was measured.
Statistical analysis. P values were calculated by Student's t-test or one-way analysis of variance followed by Bonferroni post hoc test for multiple comparisons. A chi-square analysis was used to compare frequencies. Spearman's rank correlation coefficients were used to examine the relationship with clinical data between 2 continuous variables. Values are reported as the mean AE SEM, and numbers of experiments are indicated.
RESULTS
Significantly lower expression of apelin in SSc fibroblasts than in normal fibroblasts. We first examined the expression of apelin and APJ in the skin tissue and dermal fibroblasts from SSc patients and normal individuals. The mRNA levels of apelin in the whole-skin tissue, including epidermis and dermis from affected skin lesions in SSc patients, were significantly reduced compared with those in normal individuals ( Figure 1A) . Next, we examined the expression and distribution of apelin in the skin in normal individuals and SSc patients. The summary of the quantification of apelin staining in 11 SSc patients and 8 normal individuals is provided in Supplementary Figure 1B . Immunohistochemical staining of apelin in dermal fibroblasts from SSc patients was reduced compared with that in those from normal individuals ( Figure 1B ; also see Supplementary Table 1 ). Staining of apelin in dermal small vessels from SSc patients was also reduced ( Figure 1B ; also see Supplementary Table 1 ). We also determined that apelin was expressed in CD31+ ECs and fibroblast surface protein-positive cells (which may be fibroblasts in the dermis) by immunofluorescence staining (see Supplementary Figure 1 , http://onlinelibrary.wiley.com/doi/10.1002/art.40533/ abstract).
Consistent with these findings, mRNA levels of apelin in SSc fibroblasts were significantly reduced compared with those in normal fibroblasts ( Figure 1C) . Furthermore, protein levels of apelin in SSc fibroblasts were significantly reduced ( Figures 1D and E) . Messenger RNA levels for the receptor of apelin, APJ, in normal and SSc fibroblasts were not changed ( Figure 1F ). We confirmed that the production of a-SMA, collagen a1(I), and TIMP-1 in SSc fibroblasts was significantly higher than that in normal fibroblasts (see Supplementary Figure 2 , http://onlinelibrary.wiley.com/doi/ 10.1002/art.40533/abstract). These results suggest that suppression of apelin production in dermal fibroblasts might be associated with the pathogenesis of fibrosis in SSc.
Association of decreased serum apelin levels with skin sclerosis and peripheral vasculopathy in SSc patients. To examine the association of serum apelin levels with skin sclerosis and other clinical features, such as peripheral vascular disorder, we examined serum apelin levels in 67 SSc patients. We determined that serum apelin levels were negatively correlated with the MRSS in SSc patients ( Figure 1G ). In addition, we determined that serum apelin levels were negatively correlated with the MRSS in both early (<3 years, 10 patients) and late (≥10 years, 36 patients) stages of SSc (P < 0.05 for the early stage; P < 0.01 for the late stage) (see Supplementary Figure 3A , http://onlinelibrary.wiley.com/doi/10. 1002/art.40533/abstract). Serum apelin levels did not differ between the early, middle, and late stages of the disease (see Supplementary Figure 3B ) or between lcSSc and dcSSc (see Supplementary Figure 3C ).
We also found that serum apelin levels in SSc patients with digital ulcers were significantly lower than those in patients without digital ulcers (mean AE SEM 1.76 AE 0.11 ng/ml versus 2.2 AE 0.11 ng/ml; P < 0.01) ( Figure 1H ). Serum apelin levels in SSc patients with acro-osteolysis (resorption of the terminal tuft of the digit) were also significantly lower than those in patients without acro-osteolysis (mean AE SEM 1.67 AE 0.14 ng/ml Figure 1 . Expression of apelin in systemic sclerosis (SSc) and normal fibroblasts, and serum apelin levels in SSc patients. A, Apelin mRNA in skin tissue from 4 healthy individuals and 6 SSc patients, determined using quantitative reverse transcription-polymerase chain reaction. ** = P < 0.01. B, Representative immunohistochemical staining of apelin in skin from SSc patients and normal individuals. Boxed areas in left panels are shown at higher magnification in right panels, which exhibit representative dermal small vessels (arrows) and dermal fibroblasts (arrowheads). Bars = 200 lm in left panels; 50 lm in right panels. C and F, Apelin mRNA levels (C) and APJ mRNA levels (F) in fibroblasts from 5 healthy individuals and 6 SSc patients. ** = P < 0.01. D, Expression of apelin in normal and SSc fibroblasts by immunofluorescence staining. Bar = 50 lm. Values are from 10 randomly chosen fibroblasts from 3 normal individuals and 3 SSc patients. * = P < 0.05. E, Apelin expression in 2 normal and 2 SSc fibroblasts by immunoblotting. Quantification of relative levels of apelin (normalized to GAPDH) was accomplished via densitometry using ImageJ software (National Institutes of Health) (n = 5 donors in each group). * = P < 0.05. G, Correlation of serum apelin levels with modified Rodnan skin thickness score (MRSS) in SSc patients. H, Association of serum apelin levels with clinical symptoms and organ involvement in 67 SSc patients. Values in A, C-F, and H are the mean AE SEM. versus 2.15 AE 0.1 ng/ml; P < 0.01) ( Figure 1H ). In contrast, serum apelin levels did not differ significantly between patients with and those without RP, PAH, and ILD. These results suggest that decreased serum apelin levels might be associated with skin sclerosis and peripheral vasculopathy, such as digital ulcers and acro-osteolysis, in SSc patients.
TGFb1 stimulation-induced decreased apelin synthesis in fibroblasts. Next, we assessed the effects of TGFb1 on apelin expression in normal and SSc fibroblasts. Apelin mRNA expression was significantly inhibited by TGFb1 stimulation in a dose-dependent manner in normal and SSc fibroblasts (Figures 2A and B) . In addition, levels of apelin protein were significantly decreased by TGFb1 treatment in normal and SSc fibroblasts (Figures 2A and B) . In contrast, APJ expression on the surface of normal and SSc fibroblasts was not changed by TGFb1 stimulation ( Figure 2C ). These results suggest that activation of TGFb1 signaling in SSc might be responsible for reduced apelin mRNA and protein expression in SSc fibroblasts.
Enhanced expression of a-SMA, collagen a1(I), and SPK-1 in fibroblasts resulting from siRNA depletion of apelin. Next, we analyzed the effects of siRNA depletion of apelin in normal fibroblasts (Figure 3) . The expression of apelin mRNA in normal fibroblasts treated with siRNA specific for apelin was reduced by~80% compared with that in fibroblasts treated with control siRNA. Small interfering RNA depletion of apelin significantly enhanced a-SMA and collagen a1(I) expression in normal fibroblasts. It has been reported that TGFb1 induced the expression of a-SMA and TIMP-1 via SPK-1 in dermal fibroblasts Figure 2 . Decreased apelin synthesis in fibroblasts induced by stimulation with transforming growth factor b1 (TGFb1). A, Apelin mRNA levels (left) and protein levels (right) in normal fibroblasts that were either left untreated or treated with TGFb1. B, Apelin mRNA levels (left) and protein levels (right) in systemic sclerosis (SSc) fibroblasts that were either left either untreated or treated with TGFb1. Values are the mean AE SEM from 3 experiments, relative to mRNA levels in fibroblasts not treated with TGFb1. Quantification of relative levels of apelin (normalized to GAPDH protein levels) was accomplished via densitometry using ImageJ software (National Institutes of Health) (n = 3 donors in each group). The level of apelin in untreated normal or SSc fibroblasts was assigned a value of 1. * = P < 0.05. C, APJ staining in normal and SSc fibroblasts that were either left untreated or treated with TGFb1. Bar = 50 lm. Values are the mean AE SEM from 10 randomly chosen fibroblasts from 3 normal individuals and 3 SSc patients. (33, 34) . We found that siRNA depletion of apelin significantly enhanced SPK-1 expression in normal fibroblasts. TIMP-1 mRNA expression in fibroblasts tended to be enhanced by siRNA depletion of apelin. These results suggest that apelin might have an inhibitory effect on mRNA expression of fibrosis-related genes in dermal fibroblasts.
Apelin inhibition of TGFb1/Smad signaling and of TGFb1-induced overexpression of a-SMA, collagen a1(I), TIMP-1, and SPK-1 in fibroblasts. To assess the inhibitory effect of apelin on fibrosis, we analyzed the effects of adding apelin ([Pyr   1 ]-Apelin-13) to fibroblasts. TGFb1-induced a-SMA, collagen a1(I), TIMP-1, and SPK-1 mRNA overexpression in normal fibroblasts was inhibited by the addition of apelin in a dose-dependent manner (Figures 4A-D) . TGFb1-induced a-SMA and collagen a1(I) protein expression was also inhibited by the addition of apelin, as shown by Western blot ( Figure 4E ) and immunofluorescence staining ( Figure 4G ). In addition, the expression of collagen a1(I), a-SMA, CTGF, and TIMP-1 in SSc fibroblasts was also inhibited by the addition of apelin (see Supplementary Figure 4 , http://onlinelibrary. wiley.com/doi/10.1002/art.40533/abstract).
It has been known that TGFb1 induces a-SMA, collagen a1(I), SPK-1, and TIMP-1 production via phosphorylated Smad2/3 (33-36). We found that TGFb1-induced phosphorylated Smad2/3 was inhibited by the addition of apelin ( Figure 4F ). The expression of TGFb receptor types I and II was not changed by addition of apelin (see Supplementary Figure 5 , http://onlinelibrary. wiley.com/doi/10.1002/art.40533/abstract). Administration of apelin did not affect the proliferation of fibroblasts (see Supplementary Figure 6A , http://onlinelibrary.wiley. com/doi/10.1002/art.40533/abstract), which suggests that there might be no toxicity of apelin in vitro. These results suggest that apelin might have an inhibitory action against TGFb1-induced skin fibrosis.
Significant inhibition of bleomycin-induced dermal fibrosis in mice by apelin administration. Next, we examined the effect of apelin injections on bleomycin-induced dermal fibrosis in mice. Mice with Figure 3 . Small interfering RNA (siRNA) depletion of apelin enhances expression of a-smooth muscle actin (a-SMA), collagen a1(I), and sphingosine kinase 1 (SPK-1) in fibroblasts. Shown are levels of mRNA for apelin, a-SMA, collagen a1(I), SPK-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), transforming growth factor b1 (TGFb1), and connective tissue growth factor (CTGF) in control siRNA (siCtl)-treated and apelin siRNA (siApe)-treated normal fibroblasts, determined using quantitative reverse transcription-polymerase chain reaction. Quantification was normalized to 18S ribosomal RNA levels. Values are the mean AE SEM from 7 experiments using fibroblasts from 7 different donors, relative to levels of mRNA in control siRNA-treated fibroblasts. * = P < 0.05; ** = P < 0.01.
bleomycin-induced dermal fibrosis received intraperitoneal injections of apelin or PBS. Bleomycin-enhanced dermal thickness was significantly suppressed by apelin injections (Figures 5A and B) . We confirmed that bleomycin-induced dermal fibrosis, as revealed by Masson's trichrome staining, was significantly reduced by apelin injections ( Figure 5C ). The thickness of the subcutaneous adipose layer was significantly reduced by bleomycin, and apelin injections reversed bleomycin-induced suppression (see Supplementary Figure 7 , http://onlinelibrary.wiley. com/doi/10.1002/art.40533/abstract). In addition, bleomycin-induced mRNA levels of IL-6, TGFb1, and CTGF in lesional skin were significantly decreased by apelin injections ( Figure 5D ). The numbers of a-SMA+ myofibroblasts and CD3+ T cells were enhanced in lesional skin in bleomycin-treated mice, and apelin injections inhibited the numbers of these myofibroblasts and T cells in lesional skin (Figure 5E ), while the number of CD68+ macrophages in lesional skin was not changed ( Figure 5E ). We noted the presence of dilated blood vessels in the dermis in lesional skin in apelininjected mice ( Figure 5F ). The number of CD31+ blood vessels was not changed by apelin injections ( Figure 5F ). These results suggest that apelin might inhibit skin fibrosis in vivo.
Biased agonist of APJ, MM07, inhibits TGFb1/ Smad signaling and TGFb1-induced overexpression of a-SMA and collagen a1(I) in fibroblasts in vitro and bleomycin-induced dermal fibrosis in mice. Finally, we investigated the effect of the synthetic biased agonist of APJ, MM07 (24, 25) , on fibrosis in vitro and in vivo. First, we assessed the inhibitory effect of MM07 on mRNA expression of fibrosis-related genes in fibroblasts. TGFb1-induced a-SMA and collagen a1(I) mRNA overexpression was significantly inhibited by the addition of MM07 in a dose-dependent manner ( Figures 6A and B) . Interestingly, the inhibitory effect of MM07 on TGFb1-induced gene expression in fibroblasts was higher than that of apelin ([Pyr   1 ]-Apelin-13) (compare Figures 6A and B with Figures 4A and B) . Additionally, TGFb1-induced a-SMA and collagen a1(I) protein expression was also inhibited by the addition of MM07, as shown by Western blot (Figure 6C ) and immunofluorescence staining ( Figure 6E ). TGFb1-induced phosphorylated Smad2/3 was also inhibited by the addition of MM07 ( Figure 6D ). Administration of MM07 did not affect the proliferation of fibroblasts , and SPK-1 (D) in normal fibroblasts treated with apelin and/or TGFb1 (1 ng/ml for 24 hours), determined using quantitative reverse transcription-polymerase chain reaction. E, Levels of a-SMA and collagen a1(I) protein in normal fibroblasts treated with apelin (100 nM) and/or TGFb1 (1 ng/ml), determined by immunoblotting (n = 3 donors). F, Levels of pSmad2/3 and Smad2/3 protein in normal fibroblasts treated with apelin (100 nM) and/or TGFb1 (1 ng/ml), determined by immunoblotting (n = 3 donors). Quantification of relative levels of a-SMA, collagen a1(I), and pSmad2/3 was accomplished via densitometry using ImageJ software (National Institutes of Health). The expression level in untreated fibroblasts was assigned a value of 1. Values are the mean AE SEM from 3 experiments, relative to levels of mRNA in fibroblasts treated with TGFb1 without apelin. * = P < 0.05; ** = P < 0.01 versus cells treated with TGFb1 without apelin. G, Immunofluorescence staining of a-SMA in dermal fibroblasts that were either left untreated or treated with TGFb1 (1 ng/ml) and/or apelin (100 nM) for 24 hours. Bar = 50 lm.
(see Supplementary Figure 6B , http://onlinelibrary.wiley. com/doi/10.1002/art.40533/abstract), which suggests that there might be no toxicity of MM07.
Next, we examined the effect of MM07 on bleomycin-induced dermal fibrosis in mice. Bleomycinenhanced dermal thickness was significantly inhibited . Bars = 50 lm. B, Quantification of dermal thickness of lesional skin in mice, determined in 3 random microscopic fields in 6 mice per group. D, Levels of mRNA for interleukin-6 (IL-6), transforming growth factor b1 (TGFb1), and connective tissue growth factor (CTGF) in skin of PBS-or bleomycin-treated mice subsequently injected with PBS or apelin, determined using quantitative reverse transcription-polymerase chain reaction (n = 3 mice per group), relative to levels of mRNA in skin of control mice. E, Numbers of a-smooth muscle actin (a-SMA)-positive myofibroblasts, infiltrating CD3+ T cells, and CD68+ macrophages in the dermis, determined by counting cells in 5 random microscopic fields in 3-6 mice per group. F, Representative imaging of CD31 staining of the skin in bleomycin-treated mice subsequently treated with PBS or apelin. Arrowheads indicate dilated small vessels. Bar = 50 lm. The number of CD31+ vessels in the dermis was determined by counting in 5 random microscopic fields in 3-6 mice per group. Values are the mean AE SEM. * = P < 0.05; ** = P < 0.01.
by intraperitoneal injections of MM07 (Figures 6F and G) . We confirmed that the amount of collagen in the skin revealed by Masson's trichrome staining was enhanced by bleomycin, and this enhancement was inhibited by MM07 treatment ( Figure 6H ). The numbers of a-SMA+ myofibroblasts, CD3+ T cells, and CD68+ macrophages were increased in lesional skin in bleomycin-treated mice, and MM07 injections significantly decreased the number of bleomycin-induced myofibroblasts in lesional skin ( Figure 6I ), while the number of CD68+ macrophages in lesional skin was not changed by MM07 treatment ( Figure 6I ). Similar to the results with apelin-injected mice, dilated dermal small Figure 6 . MM07 inhibits transforming growth factor b1 (TGFb1)-induced fibrosis in fibroblasts in vitro and bleomycin (Bleo)-induced dermal fibrosis in mice. A and B, Levels of mRNA for a-smooth muscle actin (a-SMA) (A) and collagen a1(I) (B) in normal fibroblasts treated with MM07 and/or TGFb1 (n = 4 donors). C and D, Levels of a-SMA and collagen a1(I) (C) and levels of pSmad2/3 and Smad2/3 (D) in normal fibroblasts treated with MM07 and/or TGFb1, determined by immunoblotting (n = 3 donors). Quantification of relative expression levels was accomplished via densitometry using ImageJ software (National Institutes of Health). Values are the mean AE SEM. * = P < 0.05; ** = P < 0.01 versus cells treated with TGFb1 without MM07. E, Immunofluorescence staining of a-SMA in fibroblasts that were either left untreated or treated with TGFb1 and/or MM07. Bar = 50 lm. F and H, Representative images of hematoxylin and eosin staining (F) or Masson's trichrome staining (H) of the skin in mice treated with subcutaneous injections of phosphate buffered saline (PBS) or bleomycin and subsequently treated with intraperitoneal injections of PBS or MM07. Bars = 50 lm. G, Quantification of dermal thickness in mice, determined in 3 random microscopic fields in 6 mice per group. I and J, Numbers of a-SMA+ myofibroblasts, CD3+ Tcells, CD68+ macrophages (I), and CD31+ vessels (J; right) in the dermis, determined by counting in 5 random microscopic fields in 6 mice per group. J, Left, Representative imaging of CD31 staining in bleomycin-treated mice treated with PBS or MM07. Arrowheads indicate dilated dermal small vessels. Bar = 50 lm. Values are the mean AE SEM. * = P < 0.05; ** = P < 0.01. vessels in lesional skin were noted in MM07-injected mice ( Figure 6J ). The number of CD31+ blood vessels was not changed by MM07 injections ( Figure 6J ).
Finally, we examined the effect of apelin/MM07 on fibrosis in the therapeutic model. Apelin/MM07 injections were initiated 7 days after starting bleomycin treatment. We found that bleomycin-enhanced dermal thickness tended to be inhibited by injections of apelin/MM07, but these differences did not reach statistical significance (see Supplementary Figure 8 , http://onlinelibrary.wiley.com/doi/ 10.1002/art.40533/abstract). The numbers of bleomycininduced a-SMA+ myofibroblasts and CD68+ macrophages were significantly decreased by apelin/MM07 injections. These results suggest that the biased agonist of APJ, MM07, might inhibit TGFb1/Smad signaling and TGFb1-induced fibrosis in fibroblasts in vitro and might inhibit skin fibrosis in vivo.
DISCUSSION
It has been reported that reduced apelin expression was associated with cardiac, renal, and pulmonary artery fibrosis (12, 19, 37) . Consistent with these findings, we determined that apelin expression was significantly reduced in SSc fibroblasts in lesional skin compared with that in normal fibroblasts. Furthermore, we found that the expression of apelin was significantly inhibited by TGFb1 stimulation in normal and SSc fibroblasts, suggesting that activation of TGFb1 signaling in SSc fibroblasts might be partly responsible for reduced apelin expression in SSc fibroblasts.
Several studies have examined serum apelin levels in patients with fibrotic diseases or SSc-related diseases. Serum apelin levels were decreased in patients with cardiac, renal, and pulmonary fibrosis and PAH (13, 38, 39) . In contrast, serum apelin levels were elevated in patients with liver fibrosis (40) . In this study, we determined that serum apelin levels were negatively correlated with skin sclerosis in SSc patients, which suggests that decreased serum apelin levels might be associated with skin fibrosis in SSc. It has been reported that apelin/APJ signaling plays an important role in the pathogenesis of cardiovascular diseases, including PAH (18) . In addition, apelin/ APJ signaling regulates cardiovascular tone, blood pressure, blood flow, and parallel alignment of arteries and veins in the skin (9-11). We found that apelin staining of dermal small vessels in SSc patients was decreased and that serum apelin levels in SSc patients with peripheral vasculopathy, such as digital ulcers and acro-osteolysis, were significantly reduced. Therefore, reduced apelin production may also be involved in the pathogenesis of peripheral vasculopathy as well as PAH in SSc.
Recent studies indicate that microRNA can regulate fibrosis in human dermal fibroblasts and may be involved in the pathogenesis of skin fibrosis in SSc (41). Nagpal et al reported that TGFb1 induced expression of miR-125b and that overexpression of miR-125b inhibited the expression of apelin in cardiac fibroblasts, suggesting that TGFb1 might suppress the expression of apelin via miR-125b in cardiac fibroblasts (37) . Apelin deficiency in pulmonary artery ECs led to increased expression of FGF-2 and FGFR-1 via decreased expression of miR-424 and miR-503 (42) . Furthermore, miR-130/301 regulated the apelin-miR-424/503-FGF-2 regulatory axis (12) . These findings suggest that microRNA may be involved in the inhibition of apelin expression in fibroblasts by TGFb1. Additional studies are warranted to elucidate the role of microRNA in the regulation of apelin expression in fibroblasts.
In SSc fibroblasts, TGFb1/Smad signaling is generally activated, resulting in myofibroblast transition and collagen overproduction (43) . TGFb1 binds to TGFb receptor types I and II, induces the phosphorylation of Smad2/3, and subsequently binds to Smad4. A Smad complex translocates to the nucleus and enhances the expression of target genes, such as those for a-SMA, collagen a1(I), and CTGF (44) . SPK-1 is an important component of TGFb1/Smad signaling and the key mediator of collagen and a-SMA production (33, 34, 45) . With respect to the regulation of TGFb1/Smad signaling by apelin, Pchejetski et al reported that apelin suppressed the expression of SPK-1 and collagen production in cardiac fibroblasts in vitro (16) . In addition, previous studies have revealed that apelin inhibited the TGFb1-induced increase of phosphorylated Smad2/3 in vitro and attenuated the up-regulation of TGFb receptor I and its downstream Smad signaling in vivo (19) .
In the present study, we assessed the role of apelin in TGFb1/Smad signaling in dermal fibroblasts. We determined that siRNA depletion of apelin enhanced a-SMA, collagen a1(I), and SPK-1 expression in fibroblasts and that addition of apelin inhibited TGFb1-induced overexpression of a-SMA, collagen a1(I), TIMP-1, SPK-1, and phosphorylated Smad2/3 in fibroblasts. However, expression of TGFb receptor types I and II was not inhibited by apelin. These results are consistent with previous findings and suggest that apelin might inhibit TGFb1/Smad signaling, myofibroblast differentiation, and TGFb1-induced skin fibrosis. These results also indicate that inhibitory regulation by apelin may be mediated by inhibition of phosphorylation of Smad2/3. However, the precise mechanisms by which apelin inhibits TGFb1/Smad signaling are unknown, and further studies are needed.
Several studies demonstrated that the administration of apelin significantly inhibited fibrosis in animal models, such as models of myocardial infarction, renal interstitial fibrosis, and pulmonary fibrosis (16, 19, 46, 47) . In our study, we demonstrated that the administration of apelin inhibited skin fibrosis in bleomycin-induced fibrosis. These in vivo results were consistent with our in vitro results, which suggested that apelin might have therapeutic potential by blocking TGFb1/Smad signaling under pathogenic conditions. We also noticed that several dermal small vessels in lesional skin were dilated in apelininjected mice, suggesting that injected apelin might act both on ECs and on fibroblasts in the skin.
Apelin produced by adipocytes acts as an adipokine (7). Several studies suggested the possible contribution of adipokines, such as leptin and adiponectin, to the pathologic process of SSc (48, 49) . Marangoni et al reported that adipose tissue loss and adipocyte-myofibroblast transition might be primary events in the pathogenesis of cutaneous fibrosis in SSc (50) . Since SSc patients had significantly lower body mass indexes and fat tissue compared with normal individuals (51), reduced fat tissue in SSc patients may subsequently result in the reduced apelin/APJ signaling in SSc fibroblasts and, in turn, in enhanced fibrosis in SSc.
Collectively, we propose a model for the role of apelin in the regulation of skin fibrosis in SSc (see Supplementary Figure 9 , http://onlinelibrary.wiley.com/doi/10.1002/ art.40533/abstract). In SSc fibroblasts, activated TGFb1 signaling inhibits apelin production, and reduced adipose tissue may lead to a decreased amount of apelin. These changes may attenuate the inhibitory effect of apelin on TGFb1/Smad signaling and collagen production, resulting in the acceleration of skin fibrosis. TGFb1 signaling and apelin signaling may counteract each other in the fibrotic process of SSc. The current findings provide new insight into the regulation of fibrosis by apelin/APJ signaling in SSc fibroblasts.
It has been reported that infusion of apelin leads to vasodilation in humans in vivo (25) . However, since chronic administration of apelin causes receptor desensitization by b-arrestin-mediated internalization of APJ, there is a limitation for the clinical use of apelin. MM07 is the cyclic apelin peptide that preferentially activates G protein responses with low potency in b-arrestin-mediated receptor internalization (24) . It is of interest that an intrabrachial infusion of MM07 increased the forearm blood flow in human volunteers without any severe adverse effects (25) . We demonstrated that MM07 inhibited TGFb1/Smad signaling and TGFb1-induced fibrosis in fibroblasts in vitro, and that administration of MM07 significantly inhibited bleomycin-induced dermal fibrosis in mice. Furthermore, we demonstrated that MM07 had greater potential than apelin to inhibit fibrosis in vivo and in vitro. These results suggest that administration of MM07 may have therapeutic efficacy for fibrosis in SSc patients. Further clinical investigation is needed to determine the efficacy and safety of the clinical use of MM07. In conclusion, the inhibitory regulation of fibrosis by apelin/APJ signaling may be involved in the pathogenesis of SSc and could be a therapeutic target for fibrosis in SSc.
